

[Bendamustine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01AA09](#)

Indication

Chronic lymphocytic leukaemia or small lymphocytic lymphoma ICD11 code: [2A82.0](#)

INN

Bendamustine

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > unspecified: 45 mg per 0.5 mL ; 180 mg per 2 mL

EML status history

First added in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Bendamustine](#)

[DrugBank](#)

[Bendamustine](#)

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for chronic lymphocytic leukaemia. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for chronic lymphocytic leukaemia is attached.